Bicara Therapeutics names Jeremy Bender, Christy Oliger to board
BCAX•Board appointments and retirement
- Bicara Therapeutics appointed Jeremy Bender, Ph.D., MBA and Christy Oliger to its board.
- Bender was CEO of Day One Biopharmaceuticals through its 2026 acquisition by Servier; he has more than 20 years of biotech strategy experience.
- Oliger most recently served as senior vice president of Genentech’s Oncology Business Unit; she has more than 30 years of commercial experience.
- Founding board member Kiran Mazumdar-Shaw retired from the board.
